News AZ's Tagrisso gets NHS funding in Scotland SMC backs drug based on feedback from patients and doctors, after rejection by NICE.
News Pfizer breast cancer drug Ibrance rejected by NICE Ibrance too expensive at almost £80,000 per course.
News Janssen's Imbruvica recommended in CLL J&J unit awaiting decisions in two more blood cancer uses.
News Pharma criticises 'heavy handed' NICE affordability test NHS England and NICE are attempting to reduce budget impact of drugs.
News Myeloma drugs Darzalex and Kyprolis rejected in Scotland SMC says "no" to Amgen and Janssen multiple myeloma drugs.
News OECD calls for 'rebalancing of power' in drug price negotiat... Health systems should fund more treatments for chronic diseases, says EFPIA
R&D The long-delayed promise of the microbiome, with Sam Possemi... Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
